THURSDAY, May 15 (HealthDay News) -- An injection of a local
anesthetic into the nerves of the neck that regulate temperature
could give breast cancer patients long-term relief from hot flashes
and sleep deprivation, a new study suggests.
Severe hot flashes often accompany treatment for breast cancer,
especially among women taking anti-estrogen drugs. These hot
flashes can become so severe that women stop taking their
medication at the risk of the cancer returning. In fact, more than
50 percent of these women stop taking their medication after 180
days, researchers report.
"Breast cancer survivors can have very severe hot flashes, and
this modality of treatment seems to resolve that without the usual
problems of hormone treatments," said lead researcher Dr. Eugene
Lipov, medical director at Advanced Pain Centers in Hoffman
Estates, Ill.
In the future, this could be how all hot flashes are treated,
Lipov said. "Fifty million older women in the United States have
hot flashes, not just breast cancer survivors, but menopausal
women," he said. "Five million of these women have severe hot
flashes."
The current treatments for hot flashes, including estrogen, all
have dangers associated with them or are ineffective, Lipov said.
"This is a safe approach that works very quickly and can last for
up to three years," he said. "The average response time is three to
eight months."
The report is published in the June issue of
The Lancet Oncology.
In the study, Lipov's team treated 13 breast cancer survivors
who had severe hot flashes, using a stellate-ganglion block. The
researchers evaluated the number of hot flashes and the quality of
the women's sleep one week before the injection and every week
thereafter for 12 weeks.
The researchers found that the total number of hot flashes
dropped from an average of 79.4 per week before the injection to an
average of 49.9 per week in the first two weeks after
treatment.
The number of hot flashes continued to decline over 12 weeks and
reached a mean of 8.1 hot flashes per week. Moreover, the number of
very severe hot flashes dropped to near zero by the end of the 12th
week, according to the report.
In addition, the number of night awakenings dropped from an
average of 19.5 per week before the injection to an average of 7.3
per week in the first two weeks after the procedure. Night
awakenings continued to decrease, to an average of 1.4 per week by
the end of the study.
"This is a big advance in treatment for women," Lipov said.
"Women with severe hot flashes should really be treated with
this."
One expert thinks that this might be a good way of controlling a
serious side effect in breast cancer treatment.
"Most women experience hot flashes," said Dr. Joanne Mortimer,
vice chairwoman of medical oncology at the City of Hope
Comprehensive Cancer Center in Duarte, Calif. "And they interfere
with normal activity in 15 percent."
"In addition, 65 percent of women treated for breast cancer
experience hot flashes, and we cannot use estrogen replacement in
these folks," Mortimer said. "Relief of symptoms is important for
all women but is especially a need in the breast cancer survivor
population."
Another expert was cautious about the benefits of this treatment
and said more data was needed before it could become widely
accepted.
"While it looks like the study produced meaningful results for
many of the women in the trial, this is a tiny study, which did not
go on for very long," said Barbara A. Brenner, executive director
of Breast Cancer Action.
Brenner added that because the procedure involves injections and
the use of fluoroscopy, which is radiation, it could increase the
risk of cancer among women who have had radiation therapy for
breast cancer.
"All of which is to say that, while some women will be so
seriously affected by hot flashes and disruptions of sleep to want
to do this, it would be good to have considerably more data both in
terms of numbers studied and long-term side effects before touting
it," Brenner said.
More information
For more on hot flashes, visit the
U.S. National Library of Medicine.